External quality assurance of HER2 fluorescence in situ hybridisation testing: Results of a UK NEQAS pilot scheme

Journal of Clinical Pathology

Volumn 60, Issue 7, 2007, Pages 816-819

  Bartlett, John M S ^a   Ibrahim, Merdol ^b   Jasani, Bharat ^c   Morgan, John M ^c   Ellis, Ian ^d   Kay, Elaine ^e   Magee, Hilary ^f   Barnett, Sarah ^b   Miller, Keith ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e BEAUMONT HOSPITAL   (Ireland)

^f ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; EARLY CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; ONCOGENE NEU; PILOT STUDY; PRIORITY JOURNAL; QUALITY CONTROL; UNITED KINGDOM;

BREAST NEOPLASMS; FEMALE; GREAT BRITAIN; HEALTH SERVICES RESEARCH; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; PILOT PROJECTS; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 34447302567     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.040840     Document Type: Article

References (16)

1. Vogel C, Cobleigh MA, Tripathy D, et al. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001;37(Suppl 1):S25-9.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Ellis IO, Bartlett J, Dowsett M, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7.
4. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol 2003;199:411-17.
5. Bartlett JMS, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422-8.
6. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(Suppl 11):46-52.
7. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
8. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
9. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23.
10. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002;94:852-4.
11. Paik S, Tan-Chiu E, Bryant J, et al. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin. Breast Cancer Res Treat 2002;76:9.
12. Bartlett JMS, Walters AD, Ballantyne SA, et al. Estimation of chromosome 9 copy number using quantitative fluorescence in situ hybridisation fish as a marker of disease recurrence in transitional cell carcinoma of the bladder. J Pathol 1997;182:A20.
13. Watters AD, Ballantyne SA, Going JJ, et al. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int 2000;85:42-7.
14. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-14.
15. Miller K, Rhodes A, Jasani B. Variation in rates of oestrogen receptor positivity in breast cancer again. BMJ 2002;324:298-9.
16. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30.